EGFR and non-small cell lung carcinoma: This study aims to compare cost and effectiveness of sintilimab plus chemotherapy, with or without bevacizumab biosimilar IBI305, against chemotherapy alone for in patients with EGFR-mutated NSCLC who progressed on EGFR TKI treatment from the Chinese healthcare perspective.